1
|
Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open 2021; 8:e6. [PMID: 34859759 PMCID: PMC8649363 DOI: 10.1192/bjo.2021.1053] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND During the first wave of the coronavirus disease 2019 (COVID-19) pandemic, patients with confirmed cases in New York State accounted for roughly 25% of total US cases, with psychiatric hospital in-patients at particularly high risk for COVID-19 infection. AIMS The beneficial effects of mental health medications, such as selective serotonin reuptake inhibitors (SSRIs), on the severity of COVID-19 disease outcomes have been documented. Protective effects against infection have also been suggested for these medications. We therefore tested the hypothesis that medication use modifies the risk of COVID-19 infection in a long-stay, chronic in-patient psychiatry setting, where the potential for exposure was likely uniform across the facility, and where these medications were routinely prescribed. METHOD This was a retrospective cohort study of an adult psychiatric facility operated by the New York State Office of Mental Health. Current medication information and COVID-19 status was collected from electronic medical records for 165 people who were in-patients during the period January to July 2020, and logistic regression was employed to model the main effects of medication use on COVID-19 infection. RESULTS A significant protective association was observed between antidepressant use and COVID-19 infection (odds ratio (OR) = 0.33, 95% CI 0.15-0.70, adjusted P < 0.05). Analysis of individual antidepressant classes showed that SSRI, serotonin-norepinephrine reuptake inhibitor and the serotonin-2 antagonist reuptake inhibitor classes of antidepressants, drove this protective effect. Exploratory analyses of individual antidepressants demonstrated an association between lower risk of infection and fluoxetine use (P = 0.023), as well as trazodone use (P = 0.001). CONCLUSIONS The novel finding of reduced COVID-19 infection risk for psychiatric in-patients taking antidepressants, suggests that antidepressants may be an important weapon in the continued fight against COVID-19 disease. This finding may become particularly salient for in-patient settings if vaccine-resistant strains of the virus appear.
Collapse
Affiliation(s)
- Catherine L Clelland
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, USA; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, USA; and Department of Psychiatry, Columbia University Irving Medical Center, USA
| | - Krista Ramiah
- Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, USA
| | - Louisa Steinberg
- Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, USA; and Department of Psychiatry, NYU Grossman School of Medicine, USA
| | - James D Clelland
- Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, USA
| |
Collapse
|
2
|
Clelland CL, Kantrowitz JT, Choo T, Clelland JD, Lieberman JA. Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. Schizophr Res 2020; 218:321-323. [PMID: 31973997 DOI: 10.1016/j.schres.2019.12.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 12/30/2019] [Accepted: 12/31/2019] [Indexed: 12/23/2022]
Affiliation(s)
- Catherine L Clelland
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.
| | - Joshua T Kantrowitz
- Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA; Schizophrenia Research Center, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
| | - Tse Choo
- New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
| | - James D Clelland
- Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
| | - Jeffrey A Lieberman
- Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
| |
Collapse
|
3
|
Affiliation(s)
- James D Clelland
- Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, United States of America; Department of Psychiatry, New York University Langone Medical Center (NYU), 550 First Avenue, New York, NY, United States of America
| | - Jennifer Smeed
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America
| | - Serge Cremers
- Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America
| | - Catherine L Clelland
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America; Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America.
| |
Collapse
|
4
|
Clelland JD, Read LL, Smeed J, Clelland CL. Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disorders. Psychiatry Res 2018; 262:229-236. [PMID: 29471261 PMCID: PMC5866784 DOI: 10.1016/j.psychres.2018.02.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 01/19/2018] [Accepted: 02/02/2018] [Indexed: 12/17/2022]
Abstract
Tetrahydrobiopterin (BH4) is an essential cofactor for dopamine, serotonin and nitric oxide synthesis. Deficits of plasma total biopterin (a measure of BH4) have been described in schizophrenia and schizoaffective disorder. GCH1 encodes the first and rate-limiting enzyme in BH4 synthesis. Peripheral GCH1 expression is lower in first episode psychosis patients versus controls, and we hypothesized that a GCH1 promoter polymorphism associated with psychiatric illness, contributes to regulation of both GCH1 expression and BH4 levels. We tested this hypothesis in 120 subjects (85 patients with schizophrenia or schizoaffective disorder and 35 controls): Patients with the rs10137071 A allele had significantly lower plasma biopterin than GG patients and controls. In additional samples we assessed the relationship between genotype and diagnosis (schizophrenia or control) on GCH1 expression in the prefrontal cortex (n = 67) and peripheral leukocytes (n = 53). We found a significant linear relationship between GCH1 and study group in the CNS and periphery, with A allele patients having lower expression. Finally, in antipsychotic naïve patients (n = 13) we tested for an effect of medication on GCH1: Expression rose significantly after the onset of medication, primarily in A allele patients. These data suggest the potential for personalized genetic approaches to ameliorating BH4 deficits in schizophrenia-spectrum disorders.
Collapse
Affiliation(s)
- James D Clelland
- Movement Disorders and Molecular Psychiatry, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, USA; Department of Psychiatry, New York University Langone Medical Center (NYU), 550 First Avenue, New York, NY, USA
| | - Laura L Read
- Movement Disorders and Molecular Psychiatry, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, USA; Department of Psychiatry, New York University Langone Medical Center (NYU), 550 First Avenue, New York, NY, USA
| | - Jennifer Smeed
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, USA
| | - Catherine L Clelland
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, USA.
| |
Collapse
|
5
|
Clelland JD, Read LL, Drouet V, Kaon A, Kelly A, Duff KE, Nadrich RH, Rajparia A, Clelland CL. Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of association. Schizophr Res 2014; 156:15-22. [PMID: 24787057 PMCID: PMC4044915 DOI: 10.1016/j.schres.2014.03.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 03/13/2014] [Accepted: 03/19/2014] [Indexed: 12/25/2022]
Abstract
25-Hydroxyvitamin D (25(OH)D) deficits have been associated with schizophrenia susceptibility and supplementation has been recommended for those at-risk. Although the mechanism by which a deficit confers risk is unknown, vitamin D is a potent transcriptional modulator and can regulate proline dehydrogenase (PRODH) expression. PRODH maps to chromosome 22q11, a region conferring the highest known genetic risk of schizophrenia, and encodes proline oxidase, which catalyzes proline catabolism. l-Proline is a neuromodulator at glutamatergic synapses, and peripheral hyperprolinemia has been associated with decreased IQ, cognitive impairment, schizoaffective disorder, and schizophrenia. We investigated the relationship between 25(OH)D and schizophrenia, comparing fasting plasma 25(OH)D in 64 patients and 90 matched controls. We then tested for a mediating effect of hyperprolinemia on the association between 25(OH)D and schizophrenia. 25(OH)D levels were significantly lower in patients, and 25(OH)D insufficiency associated with schizophrenia (OR 2.1, adjusted p=0.044, 95% CI: 1.02-4.46). Moreover, 25(OH)D insufficient subjects had three times greater odds of hyperprolinemia than those with optimal levels (p=0.035, 95% CI: 1.08-8.91), and formal testing established that hyperprolinemia is a significantly mediating phenotype that may explain over a third of the effect of 25(OH)D insufficiency on schizophrenia risk. This study presents a mechanism by which 25(OH)D insufficiency confers risk of schizophrenia; via proline elevation due to reduced PRODH expression, and a concomitant dysregulation of neurotransmission. Although definitive causality cannot be confirmed, these findings strongly support vitamin D supplementation in patients, particularly for those with elevated proline, who may represent a large subgroup of the schizophrenia population.
Collapse
Affiliation(s)
- James D. Clelland
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY,Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY
| | - Laura L. Read
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY,Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY
| | - Valérie Drouet
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Columbia University Medical Center. 630 West 168th Street. New York
| | - Angela Kaon
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY
| | - Alexandra Kelly
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Columbia University Medical Center. 630 West 168th Street. New York
| | - Karen E. Duff
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Columbia University Medical Center. 630 West 168th Street. New York,New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY
| | - Robert H Nadrich
- Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY,Bellevue Hospital Center, 462 First Avenue, New York, NY
| | - Amit Rajparia
- Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY,Bellevue Hospital Center, 462 First Avenue, New York, NY
| | - Catherine L. Clelland
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Columbia University Medical Center. 630 West 168th Street. New York
| |
Collapse
|
6
|
Clelland CL, Read LL, Panek LJ, Nadrich RH, Bancroft C, Clelland JD. Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile. PLoS One 2013; 8:e69082. [PMID: 23826396 PMCID: PMC3691117 DOI: 10.1371/journal.pone.0069082] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2012] [Accepted: 06/11/2013] [Indexed: 12/21/2022] Open
Abstract
There are currently no biological tests that differentiate patients with bipolar disorder (BPD) from healthy controls. While there is evidence that peripheral gene expression differences between patients and controls can be utilized as biomarkers for psychiatric illness, it is unclear whether current use or residual effects of antipsychotic and mood stabilizer medication drives much of the differential transcription. We therefore tested whether expression changes in first-episode, never-medicated BPD patients, can contribute to a biological classifier that is less influenced by medication and could potentially form a practicable biomarker assay for BPD. We employed microarray technology to measure global leukocyte gene expression in first-episode (n=3) and currently medicated BPD patients (n=26), and matched healthy controls (n=25). Following an initial feature selection of the microarray data, we developed a cross-validated 10-gene model that was able to correctly predict the diagnostic group of the training sample (26 medicated patients and 12 controls), with 89% sensitivity and 75% specificity (p<0.001). The 10-gene predictor was further explored via testing on an independent cohort consisting of three pairs of monozygotic twins discordant for BPD, plus the original enrichment sample cohort (the three never-medicated BPD patients and 13 matched control subjects), and a sample of experimental replicates (n=34). 83% of the independent test sample was correctly predicted, with a sensitivity of 67% and specificity of 100% (although this result did not reach statistical significance). Additionally, 88% of sample diagnostic classes were classified correctly for both the enrichment (p=0.015) and the replicate samples (p<0.001). We have developed a peripheral gene expression biomarker profile, that can classify healthy controls from patients with BPD receiving antipsychotic or mood stabilizing medication, which has both high sensitivity and specificity. Moreover, assay of three first-episode patients who had never received such medications, to first enrich the expression dataset for disease-related genes independent of medication effects, and then to test the 10-gene predictor, validates the peripheral biomarker approach for BPD.
Collapse
Affiliation(s)
- Catherine L Clelland
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.
| | | | | | | | | | | |
Collapse
|
7
|
Clelland CL, Read LL, Baraldi AN, Bart CP, Pappas CA, Panek LJ, Nadrich RH, Clelland JD. Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. Schizophr Res 2011; 131:139-45. [PMID: 21645996 PMCID: PMC3161723 DOI: 10.1016/j.schres.2011.05.006] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 05/05/2011] [Accepted: 05/09/2011] [Indexed: 10/18/2022]
Abstract
There are multiple genetic links between schizophrenia and a deficit of proline dehydrogenase (PRODH) enzyme activity. However, reports testing for an association of schizophrenia with the resulting proline elevation have been conflicting. The objectives of this study were to investigate whether hyperprolinemia is associated with schizophrenia, and to measure the relationship between plasma proline, and clinical features and symptoms of schizophrenia. We performed a cross-sectional case-control study, comparing fasting plasma proline in 90 control subjects and 64 schizophrenic patients and testing for association of mild to moderate hyperprolinemia with schizophrenia. As secondary analyses, the relationship between hyperprolinemia and five measures of clinical onset, symptoms and outcome were investigated. Patients had significantly higher plasma proline than matched controls (p<0.0001), and categorical analysis of gender adjusted hyperprolinemia showed a significant association with schizophrenia (OR 6.15, p=0.0003). Hyperprolinemic patients were significantly older at their first hospitalization (p=0.015 following correction for multiple testing). While plasma proline level was not related to total, positive or negative symptoms, hyperprolinemic status had a significant effect on length of hospital stay (p=0.005), following adjustment for race, BPRS score, and cross-sectional time from admission to proline measurement. Mild to moderate hyperprolinemia is a significant risk factor for schizophrenia, and may represent an intermediate phenotype in the disease. Hyperprolinemic patients have a significantly later age of first psychiatric hospitalization, suggestive of later onset, and hospital stays 46% longer than non-hyperprolinemic subjects. These findings have implications in the etiology of schizophrenia, and for the clinical management of these patients.
Collapse
Affiliation(s)
- Catherine L. Clelland
- Department of Pathology and Cell Biology, and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain. Columbia University Medical Center. 630 West 168th Street. New York.
| | - Laura L. Read
- Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY.
,Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| | - Amanda N. Baraldi
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| | - Corinne P. Bart
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| | - Carrie A. Pappas
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| | - Laura J. Panek
- Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| | - Robert H. Nadrich
- Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY.
,Bellevue Hospital Center, 462 First Avenue, New York, NY.
| | - James D. Clelland
- Department of Psychiatry, New York University Langone Medical Center, 550 First Avenue. New York, NY.
,Movement Disorders and Molecular Psychiatry. The Nathan Kline Institute for Psychiatric Research. 140 Old Orangeburg Road. Orangeburg. NY.
| |
Collapse
|
8
|
Richardson MA, Read LL, Reilly MA, Clelland JD, Clelland CLT. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem Res 2007; 32:107-13. [PMID: 17160504 DOI: 10.1007/s11064-006-9233-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2006] [Accepted: 11/16/2006] [Indexed: 10/23/2022]
Abstract
Tetrahydrobiopterin (BH4) is an essential cofactor for amine neurotransmitter synthesis. BH4 also stimulates and modulates the glutamatergic system, and regulates the synthesis of nitric oxide by nitric oxide synthases. A connection between BH4 deficiencies and psychiatric disorders has been previously reported; major depression and obsessive-compulsive disorder have been found in subjects with a BH4 deficiency disorder and more recently we have observed a robust plasma deficit of biopterin (a measure of BH4), in a large group of schizophrenic patients compared to control subjects. To extend our previous finding in schizophrenia, we analyzed plasma biopterin levels from patients with schizoaffective and bipolar disorders. A significant difference in biopterin was seen among the diagnostic groups (P < 0.0001). Post hoc analyses indicated significant biopterin deficits relative to the normal control group for the schizoaffective group, who had biopterin levels comparable to the schizophrenic group. Bipolar disorder subjects had plasma biopterin levels that were higher that the schizoaffective disorder group and significantly higher than the schizophrenic group. The demonstrated significant biopterin deficit in both schizophrenia and schizoaffective disorder, may suggest an etiological role of a BH4 deficit in these two disorders, via dysregulation of neurotransmitter systems.
Collapse
Affiliation(s)
- Mary Ann Richardson
- Movement Disorders and Molecular Psychiatry, The Nathan S. Kline Institute for Psychiatric Research, New York State Office of Mental Health, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
| | | | | | | | | |
Collapse
|
9
|
|
10
|
Clelland CL, Ferris SH, Read LL, Clelland JD, Cocchiola J, Waters R, Oo T, Vedvyas A. P3–097: Classifying Alzheimer's disease through multigene expression signature profiling. Alzheimers Dement 2006. [DOI: 10.1016/j.jalz.2006.05.1364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Catherine L. Clelland
- Mount Sinai School of MedicineNew York CityNYUSA
- The Nathan Kline InstituteOrangeburgNYUSA
| | | | - Laura L. Read
- The Nathan Kline InstituteOrangeburgNYUSA
- NYU School of MedicineNew York CityNYUSA
| | - James D. Clelland
- The Nathan Kline InstituteOrangeburgNYUSA
- NYU School of MedicineNew York CityNYUSA
| | - Jaclyn Cocchiola
- Mount Sinai School of MedicineNew York CityNYUSA
- The Nathan Kline InstituteOrangeburgNYUSA
| | | | - Thet Oo
- NYU School of MedicineNew York CityNYUSA
| | | |
Collapse
|
11
|
Abstract
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD.
Collapse
Affiliation(s)
- Mary Ann Richardson
- Movement Disorders and Molecular Psychiatry Division, Nathan Kline Institute for Psychiatric Research, New York State Office of Mental Health, Orangeburg, New York 10962, USA
| | | | | | | | | |
Collapse
|
12
|
Richardson MA, Read LL, Taylor Clelland CL, Reilly MA, Chao HM, Guynn RW, Suckow RF, Clelland JD. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 2005; 52:190-201. [PMID: 16244500 DOI: 10.1159/000089002] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Tetrahydrobiopterin (BH(4)) is a vital cofactor maintaining availability of the amine neurotransmitters [dopamine (DA), noradrenaline (NA), and serotonin (5-HT)], regulating the synthesis of nitric oxide (NO) by nitric oxide synthase (NOS), and stimulating and modulating the glutamatergic system (directly and indirectly). These BH(4) properties and their potential relevance to schizophrenia led us to investigate the hypothesis of a study group (healthy controls, n=37; schizophrenics, n=154) effect on fasting plasma total biopterin levels (a measure of BH(4)). Study analysis showed a highly significant deficit of total biopterins for the schizophrenic sample after partialling out the effects of potential confounds of gender, age, ethnicity, neuroleptic use history and dose of current use, 24-hour dietary phenylalanine/protein ratio (a dietary variable relevant to BH(4) synthesis), and plasma phenylalanine (which stimulates BH(4) synthesis). A mean decrement of 34% in plasma total biopterins for schizophrenics from control values supports clinical relevance for the finding. In a subsample (21 controls and 23 schizophrenics), sequence analysis was done of the GTP cyclohydrolase I feedback regulatory gene and no mutations were found in the coding region of the gene. A deficiency of BH(4) could lead to hypofunction of the systems of DA, NA, 5-HT, NOS/NO, and glutamate, all of which have been independently implicated in schizophrenia psychopathology. Further, evidence has been accumulating which implicates the critical interdependence of these neurotransmitter systems in schizophrenia; this concept, along with the present study finding of a biopterin deficit, suggests that further study of the BH(4) system in schizophrenia is warranted and desirable.
Collapse
Affiliation(s)
- M A Richardson
- The Nathan S. Kline Institute for Psychiatric Research, New York State Office of Mental Health, Orangeburg, NY 10962, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
BACKGROUND A series of studies had demonstrated that deficient clearance of the large neutral amino acid phenylalanine was associated with tardive dyskinesia (TD), that the administration of the branched chain amino acids (BCAA) significantly decreased TD symptoms over placebo, and that the observed TD symptom reduction was significantly correlated with a diminished availability of phenylalanine to the brain of adult men with psychosis. As part of an initiative by the National Institute of Mental Health to expand the testing of treatments that were successful in adults to children and adolescents, the present pilot study was undertaken to test whether the BCAA would also reduce TD symptoms in children and adolescents. A 2-week trial of the BCAA was thus conducted in 6 children and adolescents (age range, 10.5-16.5 years) for the treatment of TD symptoms. METHOD A clinical diagnosis of TD was made in all subjects on the basis of a global score derived from the Simpson Abbreviated Dyskinesia Rating Scale. Subjects were videotaped for TD evaluation at baseline and after 1 and 2 weeks of BCAA treatment given in the form of a drink administered 3 times daily. TD symptom change over the trial period was evaluated by researchers blinded to the treatment status of the evaluation. RESULTS TD symptom decreases were substantial in 5 of the 6 participants, ranging from 40% to 65%. Two of the subjects received an additional course of treatment, and further reductions in TD symptoms over those seen in the 2-week trial were observed. CONCLUSION The substantial symptom decrease and tolerability observed suggest the use of the BCAA formulation for the treatment of TD in children and adolescents and warrant further large-scale studies.
Collapse
Affiliation(s)
- Mary Ann Richardson
- Movement Disorders and Molecular Psychiatry Division, Nathan Kline Institute for Psychiatric Research, New York State Office of Mental Health, Orangeburg, NY 10962, USA.
| | | | | | | | | |
Collapse
|
14
|
Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, Maher TJ, Citrome L. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003; 160:1117-24. [PMID: 12777270 DOI: 10.1176/appi.ajp.160.6.1117] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested. METHOD Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements. RESULTS A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antipsychotic and glucose plasma levels. A mechanism of response related to decreased amine neurotransmitter synthesis was suggested by the significant positive correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic amino acid plasma concentrations over the course of the trial. CONCLUSIONS Branched-chain amino acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providing significant improvement in the diseased physiognomy of the afflicted person.
Collapse
Affiliation(s)
- Mary Ann Richardson
- Division of Movement Disorders and Molecular Psychiatry, Nathan S. Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Richardson MA, Read LL, Clelland JD, Chao HM, Reilly MA, Romstad A, Suckow RF. Phenylalanine hydroxylase gene in psychiatric patients: screening and functional assay of mutations. Biol Psychiatry 2003; 53:543-53. [PMID: 12644360 DOI: 10.1016/s0006-3223(02)01528-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Reports relating phenylalanine kinetics and metabolism to psychiatric disorders led us to undertake the comprehensive screening of the phenylalanine hydroxylase (PAH) coding region and functional testing of discovered mutations in a sample of psychiatric patients and healthy control subjects. METHODS Genomic DNA from psychiatric patients and control subjects was assayed for sequence variants in all PAH coding regions and splice junctions. In vivo functional analysis of mutations was conducted by assessing the kinetics and conversion to tyrosine of a standardized phenylalanine dose and by measuring fasting pterin levels. RESULTS A known missense mutation was observed in a schizoaffective subject, and a novel missense mutation was discovered in four subjects with schizophrenia and one normal subject. The schizoaffective patient heterozygous for the known A403V mutation showed the lowest rate of phenylalanine kinetics and lowest conversion to tyrosine in the patient sample. The four schizophrenic patients heterozygous for the novel K274E mutation showed significantly decreased phenylalanine kinetics, reduced conversion to tyrosine, and increased synthesis of the PAH cofactor tetrahydrobiopterin compared with schizophrenic subjects without the mutation. CONCLUSIONS The study findings suggest that larger scale studies are warranted to test the relationship of the PAH genotype with a psychiatric phenotype.
Collapse
Affiliation(s)
- Mary Ann Richardson
- Nathan S. Kline Institute for Psychiatric Research, New York State Office of Mental Health, Orangeburg 10962, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Cell adhesion to individual macromolecules of the extracellular matrix has dramatic effects on the subcellular localization of the actin-bundling protein fascin and on the ability of cells to form stable fascin microspikes. The actin-binding activity of fascin is down-regulated by phosphorylation, and we used two differentiated cell types, C2C12 skeletal myoblasts and LLC-PK1 kidney epithelial cells, to examine the hypothesis that cell adhesion to the matrix components fibronectin, laminin-1, and thrombospondin-1 differentially regulates fascin phosphorylation. In both cell types, treatment with the PKC activator 12-tetradecanoyl phorbol 13-acetate (TPA) or adhesion to fibronectin led to a diffuse distribution of fascin after 1 h. C2C12 cells contain the PKC family members alpha, gamma, and lambda, and PKCalpha localization was altered upon cell adhesion to fibronectin. Two-dimensional isoelectric focusing/SDS-polyacrylamide gels were used to determine that fascin became phosphorylated in cells adherent to fibronectin and was inhibited by the PKC inhibitors calphostin C and chelerythrine chloride. Phosphorylation of fascin was not detected in cells adherent to thrombospondin-1 or to laminin-1. LLC-PK1 cells expressing green fluorescent protein (GFP)-fascin also displayed similar regulation of fascin phosphorylation. LLC-PK1 cells expressing GFP-fascin S39A, a nonphosphorylatable mutant, did not undergo spreading and focal contact organization on fibronectin, whereas cells expressing a GFP-fascin S39D mutant with constitutive negative charge spread more extensively than wild-type cells. In contrast, C2C12 cells coexpressing S39A fascin with endogenous fascin remained competent to form microspikes on thrombospondin-1, and cells that expressed fascin S39D attached to thrombospondin-1 but did not form microspikes. Blockade of PKCalpha activity by TPA-induced down-regulation led to actin association of wild-type fascin in fibronectin-adherent C2C12 and LLC-PK1 cells but did not alter the distribution of S39A or S39D fascins. The association of fascin with actin in fibronectin-adherent cells was also evident in the presence of an inhibitory antibody to integrin alpha5 subunit. These novel results establish matrix-initiated PKC-dependent regulation of fascin phosphorylation at serine 39 as a mechanism whereby matrix adhesion is coupled to the organization of cytoskeletal structure.
Collapse
Affiliation(s)
- J C Adams
- Medical Research Council-Laboratory for Molecular Cell Biology and Department of Biochemistry and Molecular Biology, University College London, London WC1E 6BT, United Kingdom.
| | | | | | | | | | | |
Collapse
|
17
|
Lüdecke B, Knappskog PM, Clayton PT, Surtees RA, Clelland JD, Heales SJ, Brand MP, Bartholomé K, Flatmark T. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996; 5:1023-8. [PMID: 8817341 DOI: 10.1093/hmg/5.7.1023] [Citation(s) in RCA: 129] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Tyrosine hydroxylase (TH) catalyzes the conversion of L-tyrosine to L-dihydroxyphenylalanine (L-DOPA), the rate-limiting step in the biosynthesis of dopamine. This report describes a missense point mutation in the human TH (hTH) gene in a girl presenting parkinsonian symptoms in early infancy and a very low level of the dopamine metabolite homovanillic acid in the CSF. DNA sequencing revealed a T614-to-C transition in exon 5 (L205P). Both parents and the patient's brother are heterozygous for the mutation. Site-directed mutagenesis and expression in different systems revealed that the recombinant mutant enzyme had a low homospecific activity, i.e. approximately 1.5% of wt-hTH in E. coli and approximately 16% in a cell-free in vitro transcription-translation system. When transiently expressed in human embryonic kidney (A293) cells a very low specific activity (approximately 0.3% of wt-hTH) and immunoreactive hTH (< 2%) was obtained. The expression studies are compatible with the severe clinical phenotype of the L205P homozygous patient carrying this recessively inherited mutation. Treatment with L-DOPA resulted in normalisation of the CSF homovanillic acid concentration and a sustained improvement in parkinsonian symptoms.
Collapse
Affiliation(s)
- B Lüdecke
- University Children's Hospital, Bochum, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Clelland JD, Brand MP, Bolaños JP, Surtees RA, Land JM, Heales SJ. Age dependent changes in the cerebrospinal fluid concentration of nitrite and nitrate. Ann Clin Biochem 1996; 33 ( Pt 1):71-2. [PMID: 8929071 DOI: 10.1177/000456329603300111] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J D Clelland
- Division of Biochemistry and Genetics, Institute of Child Health, London, UK
| | | | | | | | | | | |
Collapse
|
19
|
Clelland JD, Edwards LG, Allen RE, Thornalley PJ. Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathione derivatives. Biochem Soc Trans 1993; 21:165S. [PMID: 8359418 DOI: 10.1042/bst021165s] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- J D Clelland
- Department of Chemistry and Biological Chemistry, University of Essex, Colchester, U.K
| | | | | | | |
Collapse
|
20
|
Edwards LG, Clelland JD, Thornalley PJ. Mechanism of the inhibition of growth of human leukaemia 60 cells by S-D-lactoylglutathione. Biochem Soc Trans 1993; 21:166S. [PMID: 8359419 DOI: 10.1042/bst021166s] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- L G Edwards
- Department of Chemistry and Biological Chemistry, University of Essex, Colchester, U.K
| | | | | |
Collapse
|
21
|
Edwards L, Clelland JD, Thornalley PJ. Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-D-lactoylglutathione in vitro. Leuk Res 1993; 17:305-10. [PMID: 8487580 DOI: 10.1016/0145-2126(93)90017-f] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The mechanism of the inhibition of proliferation of human leukaemia 60 (HL60) cells by S-D-lactoylglutathione in vitro was investigated. The median inhibitory concentration IC50 value was 66 microM (95% C.I. 50-87 microM; n = 18). The inhibition of leukaemia cell growth required exposure of HL60 cells to S-D-lactoylglutathione (and metabolites) for 12 h, with maximum growth inhibition achieved after 24 h. Removal and replacement of culture medium within the initial 12 h of culture prevented inhibition of growth and toxicity. S-D-lactoylglutathione was consumed within the initial 3 h of culture. Pretreatment of culture medium containing 10% foetal calf serum for 3 h produced no subsequent inhibition of HL60 cell growth. Incubation of HL60 cells in culture medium with low serum content (5% v/v) produced a decreased rate of cell proliferation and a decreased response to S-D-lactoylglutathione. S-D-lactoylglutathione inhibited uptake of 3H-thymidine into DNA in the third hour of culture where the median inhibitory concentration IC50 value was 74 microM (95% C.I. 51-102; n = 10). The mechanism of inhibition of HL60 cell growth by S-D-lactoylglutathione is unknown but may be cell cycle related, mediated by inhibition of DNA synthesis and involve an active metabolite which may be removed and/or inactivated by a change in culture medium.
Collapse
Affiliation(s)
- L Edwards
- Department of Chemistry and Biological Chemistry, University of Essex, Colchester, U.K
| | | | | |
Collapse
|
22
|
Clelland JD, Allen RE, Thornalley PJ. Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathiones and monoethyl ester derivatives. Biochem Pharmacol 1992; 44:1953-9. [PMID: 1449514 DOI: 10.1016/0006-2952(92)90097-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
S-2-Hydroxyacylglutathione derivatives were found to induce growth arrest and toxicity in human leukaemia 60 cells in culture. S-D-Lactoylglutathione was the most effective with a median inhibitory concentration IC50 of 82 microM (95% C.I. 65-105 microM). No similar toxicity was induced by reduced glutathione and/or the corresponding aldonic acid (500 microM) in human leukaemia 60 cells, nor by S-D-lactoylglutathione (500 microM) in mature human neutrophils under the same culture conditions. Monoethyl ester derivatives of the S-2-hydroxyacylglutathiones were prepared and also induced growth arrest and toxicity but were less effective than the corresponding unesterified compounds. S-2-Hydroxyacylglutathione derivatives also inhibited the incorporation of [3H]thymidine into DNA early in the development of toxicity: for S-D-lactoylglutathione, the median inhibitory concentration was 74 microM (95% C.I. 47-116 microM). The mechanism of the inhibition of human leukaemia cell growth by S-D-lactoylglutathione and other S-2-hydroxyacylglutathione derivatives is unknown but appears to be mediated by the inhibition of DNA synthesis.
Collapse
Affiliation(s)
- J D Clelland
- Department of Chemistry and Biological Chemistry, University of Essex, Colchester, U.K
| | | | | |
Collapse
|
23
|
Clelland JD, Thornalley PJ. S-2-hydroxyacylglutathione-derivatives: enzymatic preparation, purification and characterisation. ACTA ACUST UNITED AC 1991. [DOI: 10.1039/p19910003009] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|